These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 17530036)

  • 21. NONMEM analysis in determining the tri-exponential disposition of cefotaxime: a method of evaluating serum and urinary phase I data.
    Weber W; Harnisch L; Zimmer M; Rokitta C; Mendes P
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):560-4. PubMed ID: 8574507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and safety of cefditoren pivoxil in treatment of respiratory infections, a clinical study].
    Li JT; Gao L; Xue F; Hao FL; Wang Q; Cai BQ; Gan CL; Liu YN; Yu BX; He LX; Hu BJ; Chen XH; Zheng JC; Yu YS; Lu FF; Liang DR; Cai YN; Kang J; Kong LF; Xiao ZL; Zheng JP; Liu J; Yang WX; Zhou J
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):391-4. PubMed ID: 12820915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I clinical trial of cefditoren pivoxil (ME1207). Tolerance in healthy volunteers.
    Li JT; Hou F; Lu H; Li TY; Li H
    Drugs Exp Clin Res; 1997; 23(3-4):131-8. PubMed ID: 9403274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial.
    Sadahira T; Wada K; Araki M; Ishii A; Takamoto A; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y; Kumon H;
    J Antimicrob Chemother; 2017 Feb; 72(2):529-534. PubMed ID: 27733519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form.
    Schuck EL; Dalhoff A; Stass H; Derendorf H
    Infection; 2005 Dec; 33 Suppl 2():22-8. PubMed ID: 16518708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
    Addy C; Li S; Agrawal N; Stone J; Majumdar A; Zhong L; Li H; Yuan J; Maes A; Rothenberg P; Cote J; Rosko K; Cummings C; Warrington S; Boyce M; Gottesdiener K; Stoch A; Wagner J
    J Clin Pharmacol; 2008 Apr; 48(4):418-27. PubMed ID: 18258750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
    Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T
    J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacokinetics of subcutaneously injected Bimosiamose disodium in healthy male volunteers.
    Meyer M; Beyer D; Vollhardt K; Woischwill C; Jilma B; Wolff G
    Biopharm Drug Dispos; 2007 Dec; 28(9):475-84. PubMed ID: 17876866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
    Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA
    Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects.
    Mant T; Jurcevic S; Szakacs C; Adams L; Boland J; Hewitt LA
    Clin Ther; 2008 Jan; 30(1):131-42. PubMed ID: 18343249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
    Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections.
    Granizo JJ; Aguilar L; Gimenez MJ; Coronel P; Gimeno M; Prieto J
    Rev Esp Quimioter; 2009 Jun; 22(2):57-61. PubMed ID: 19544097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
    Lodise TP; Kinzig-Schippers M; Drusano GL; Loos U; Vogel F; Bulitta J; Hinder M; Sörgel F
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1945-51. PubMed ID: 17485507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
    Mouton JW; Punt N; Vinks AA
    Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis.
    Monmaturapoj T; Montakantikul P; Mootsikapun P; Tragulpiankit P
    Int J Infect Dis; 2012 Dec; 16(12):e843-9. PubMed ID: 22951426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.
    Sarich TC; Schützer KM; Wollbratt M; Wall U; Kessler E; Eriksson UG
    J Clin Pharmacol; 2004 Aug; 44(8):935-41. PubMed ID: 15286098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion.
    Jaruratanasirikul S; Raungsri N; Punyo J; Sriwiriyajan S
    J Antimicrob Chemother; 2005 Dec; 56(6):1163-5. PubMed ID: 16234333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.
    Boothe DM; Perkins J
    J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.